Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects WithElevated Risk

29 August 2017 (17:00 - 17:15)

Organised by:

About the speaker

Professor Terje Rolf Pedersen

Ulleval University Hospital, Oslo (Norway)

5 More presentations in this session

Presentation thumbnail

Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen of Naproxen

Professor S. Nissen (Cleveland, US)

Presentation thumbnail

Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV trial

Professor S. Nicholls (Melbourne, AU)

Presentation thumbnail

Empagliflozin reduces mortality in patients with type 2 diabetes after coronary artery bypass graft surgery: A sub-analysis of the EMPA-REG OUTCOME trial

Professor S. Verma (Toronto, CA)

Presentation thumbnail

Blood Pressure Levels for Initiation of Antihypertensive Drug Therapy and Targets of Blood Pressure Lowering in Intermediate Risk People without Cardiovascular Disease: Insights from the HOPE-3 Trial

Professor E. Lonn (Hamilton, CA)

Presentation thumbnail

One year clinical outcome of Early Administration of intravenous Beta blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention.

Doctor V. Roolvink (Zwolle, NL)

Access the full session

Session thumbnail

Clinical Trial Update 2

The Event

ESC Congress 2017

29 August 2017 17:00 CET

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources